Biotech · Private company
Calithera Biosciences, Inc
Track this companyFree. Adds Calithera Biosciences, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials251 recruiting or active
Pipeline programs40From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline40
- CabozantinibPhase 2 · Advanced Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Carboplatin ChemotherapyPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CB-839Phase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- CB-839Phase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- CB-839Phase 2 · Clear Cell Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- CB-839Phase 2 · Clear Cell Renal Cell Carcinoma (ccRCC)ClinicalTrials.gov · fetched Nov 12, 2026
- CB-839Phase 2 · Advanced Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- everolimusPhase 2 · Clear Cell Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- ExemestanePhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Folic acid 400 -1000 μgPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 2 · Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- MivavotinibPhase 2 · Non-GCB/ABC Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · Clear Cell Renal Cell Carcinoma (ccRCC)ClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Palbociclib Oral Capsule or Tablet [Ibrance]Phase 2 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab ImmunotherapyPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Pemetrexed ChemotherapyPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- SapanisertibPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- SapanisertibPhase 2 · Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- TAK-659Phase 2 · Acute Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- TAK-659Phase 2 · Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- TalazoparibPhase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- TelaglenastatPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Telaglenestat (CB-839)Phase 2 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- CB-280Phase 1 · Cystic FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- CB-839Phase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- CB-CaboPhase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- CB-ErlPhase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- CBDPhase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- CBEPhase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 1 · Triple-Negative Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- NKTR-214Phase 1 · Lymphoma, Non-HodgkinClinicalTrials.gov · fetched Nov 12, 2026
- Pac-CBPhase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- SapanisertibPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- TAK-659Phase 1 · Triple-Negative Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- TAK-659Phase 1 · Advanced Solid Tumor and Lymphoma MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- TAK-659Phase 1 · Lymphoma, MalignantClinicalTrials.gov · fetched Nov 12, 2026
- TAK-659Phase 1 · Lymphoma, Non-HodgkinClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 1 · Lymphoma, Non-HodgkinClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Glutaminase Inhibition and Chemoradiation in Advanced Cervical CancerPHASE2 · NOT_YET_RECRUITING · started Dec 31, 2026ClinicalTrials.gov NCT05521997 · fetched Nov 12, 2026
- Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)PHASE2 · TERMINATED · started Jun 23, 2022ClinicalTrials.gov NCT05319028 · fetched Nov 12, 2026
- Telaglenastat + Talazoparib In Prostate CancerPHASE2 · WITHDRAWN · started Jul 1, 2021ClinicalTrials.gov NCT04824937 · fetched Nov 12, 2026
- NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) TrialTERMINATED · started Jan 19, 2021ClinicalTrials.gov NCT04698681 · fetched Nov 12, 2026
- KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLCPHASE2 · TERMINATED · started Jul 24, 2020ClinicalTrials.gov NCT04265534 · fetched Nov 12, 2026
- Study to Evaluate the Safety of CB-280 in Patients With Cystic FibrosisPHASE1 · COMPLETED · started Jul 3, 2020ClinicalTrials.gov NCT04279769 · fetched Nov 12, 2026
- A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid TumorsPHASE1_PHASE2 · COMPLETED · started Jun 25, 2019ClinicalTrials.gov NCT03965845 · fetched Nov 12, 2026
- Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid TumorsPHASE1_PHASE2 · TERMINATED · started May 20, 2019ClinicalTrials.gov NCT03875313 · fetched Nov 12, 2026
- A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)PHASE1 · WITHDRAWN · started Apr 3, 2019ClinicalTrials.gov NCT03772288 · fetched Nov 12, 2026
- CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell CarcinomaPHASE2 · COMPLETED · started Apr 24, 2018ClinicalTrials.gov NCT03428217 · fetched Nov 12, 2026
- A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid TumorPHASE1 · WITHDRAWN · started Feb 28, 2018ClinicalTrials.gov NCT03359733 · fetched Nov 12, 2026
- A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin LymphomaPHASE1 · COMPLETED · started Feb 16, 2018ClinicalTrials.gov NCT03357627 · fetched Nov 12, 2026
- TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)PHASE2 · TERMINATED · started Oct 10, 2017ClinicalTrials.gov NCT03123393 · fetched Nov 12, 2026
- CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)PHASE2 · COMPLETED · started Sep 6, 2017ClinicalTrials.gov NCT03163667 · fetched Nov 12, 2026
- Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal CancerPHASE1_PHASE2 · COMPLETED · started Aug 23, 2017ClinicalTrials.gov NCT03263429 · fetched Nov 12, 2026
- Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell CarcinomaPHASE2 · COMPLETED · started Aug 1, 2017ClinicalTrials.gov NCT03097328 · fetched Nov 12, 2026
- Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)PHASE2 · COMPLETED · started May 1, 2017ClinicalTrials.gov NCT03057600 · fetched Nov 12, 2026
- A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid TumorsPHASE1 · TERMINATED · started Aug 12, 2016ClinicalTrials.gov NCT02834247 · fetched Nov 12, 2026
- Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)PHASE1_PHASE2 · TERMINATED · started Aug 1, 2016ClinicalTrials.gov NCT02771626 · fetched Nov 12, 2026
- Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor TherapyPHASE2 · COMPLETED · started Jul 28, 2016ClinicalTrials.gov NCT02756364 · fetched Nov 12, 2026
- Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)PHASE1_PHASE2 · TERMINATED · started Mar 9, 2015ClinicalTrials.gov NCT02323113 · fetched Nov 12, 2026
- Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid TumorsPHASE1 · COMPLETED · started Sep 15, 2014ClinicalTrials.gov NCT02197572 · fetched Nov 12, 2026
- Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast CancerPHASE2 · COMPLETED · started Feb 13, 2014ClinicalTrials.gov NCT02049957 · fetched Nov 12, 2026
- Study of the Glutaminase Inhibitor CB-839 in Solid TumorsPHASE1 · COMPLETED · started Feb 1, 2014ClinicalTrials.gov NCT02071862 · fetched Nov 12, 2026
- A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma MalignanciesPHASE1 · COMPLETED · started Dec 31, 2013ClinicalTrials.gov NCT02000934 · fetched Nov 12, 2026